GEN News Highlights

Better Skin and Hair via Synthetic Biology

(Page
1
of
1)

Intrexon has agreed to work with Johnson & Johnson Innovation and J&J Consumer & Personal Products Worldwide through a R&D collaboration aimed at creating new skin and hair care products.

“By combining Intrexon's synthetic biology approaches with the capabilities at Johnson & Johnson, we believe that there are multiple areas for new product exploration,” said Randal J. Kirk, chairman and CEO of Intrexon.

Although Intrexon has developed several core technologies, company officials referred to its UltraVector® platform in the J&J deal. Intrexon describes UltraVector as an operating system that involves DNA construction technologies, cellular and protein engineering, computational models and statistical methods.

“[The platform can] facilitate the rapid design, testing, and production of complex biological systems,” explained a company spokesperson. “In addition to hosting all of the design, build and testing capabilities within one cohesive platform, UltraVector learns by amassing a wealth of data over iterative experiments in this process. The platform is also capable of incorporating supplementary technologies, which can be selectively utilized depending on the desired biofunction.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.